Safety of bedaquiline- and delamanid-containing treatment regimens in the TBendTB cohort.

AEs often associated with linezolid and injectable drugs were more frequent than those often attributed to bedaquiline and delamanid. MDR-TB treatment monitoring and drug duration should reflect the expected safety profiles of the drug combinations.